An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder

Overview of attention for article published in Therapeutics and Clinical Risk Management, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#27 of 1,325)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 10 news outlets

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 22 Mendeley

Summary News Wikipedia Dimensions citations

So far, Altmetric has seen 10 news stories from 10 outlets.

Medicamento para la vejiga hiperactiva recomendado en Europa

Espanol.news, 29 Apr 2024

Debe concederse una autorización de comercialización para el medicamento Obgemsa ( vibegrón ) para el tratamiento de adultos…

Drug for Overactive Bladder Recommended in Europe

Medscape, 26 Apr 2024

A marketing authorization should be given for the medicinal product Obgemsa (vibegron) for treating adults with overactive…

News story from Finanz Nachrichten on Tuesday 22 March 2022

Finanz Nachrichten, 22 Mar 2022

Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management

The Daily Times, 22 Mar 2022

- Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 6 additional news stories.